Singapore markets closed

Molecular Templates, Inc. (MTEM)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.5410-0.0344 (-5.98%)
At close: 03:59PM EST

Molecular Templates, Inc.

9301 Amberglen Boulevard
Suite 100
Austin, TX 78729
United States
512 869 1555

Full-time employees224

Key executives

NameTitlePayExercisedYear born
Dr. Eric E. Poma Ph.D.CEO, Chief Scientific Officer & Director839.67kN/A1972
Ms. Jason S KimPres, COO, Interim CFO, Treasurer and Principal Financial & Accounting Officer600.41kN/A1975
Dr. Roger J. Waltzman M.B.A., M.D.Chief Medical Officer594.17kN/A1968
Ms. Megan C. FiloonGen. Counsel & Sec.N/AN/AN/A
Mr. Kurt ElsterExec. VP of Corp. Devel.N/AN/A1967
Dr. Jack Higgins Ph.D.Exec. VP of Operations & Head of ManufacturingN/AN/A1980
Dr. Erin Willert Ph.D.Exec. VP of R&DN/AN/A1982
Dr. Jen-Sing Liu Ph.D.Exec. VP of ManufacturingN/AN/A1963
Mr. Michael DowdSr. VP of Project & Alliance ManagementN/AN/AN/A
Mr. Ryan HawkinsSr. VP & Head of ManufacturingN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Corporate governance

Molecular Templates, Inc.’s ISS governance QualityScore as of 1 February 2023 is 7. The pillar scores are Audit: 10; Board: 7; Shareholder rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.